SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as its community aggressively pushes for a breakout past key market cap milestones while actively recruiting new holders through viral social media engagement and airdrop incentives. Supporters are rallying around the project's organic growth and the lack of a formal chart, framing the current price action as an accumulation phase before an anticipated significant move upward.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings Inc. (ASRT) is currently trending as shareholders voice intense frustration over a cash-tender acquisition by Garda Therapeutics at an offer price they perceive as a severe undervaluation. The community is actively debating the deal's fairness, potential conflicts of interest among board members, and legal strategies to challenge or block the acquisition, with many arguing that the company's asset value and Rolvedon's market prospects warrant a significantly higher valuation.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently facing intense community debate as retail investors clash over its volatile price action, with many warning of a potential bubble due to the company's lack of consistent profitability and looming dilution risks. While some traders are riding the aggressive momentum tied to the semiconductor materials sector, others are aggressively shorting the stock, citing heavy insider selling and unsustainable valuation gaps as signs of an inevitable correction.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing a tug-of-war between institutional optimism and lingering geopolitical anxiety, as traders monitor massive ETF inflows against potential supply-chain disruptions in the Strait of Hormuz. The community remains deeply divided, with bulls pointing to technical breakouts and supply squeezes while bears warn that unresolved regional conflicts could trigger renewed volatility.

Energous Corp. engages in the development of wireless charging technology. It focuses on the product, WattUp, a wireless power technology consisting of proprietary semiconductor chipsets, software controls, hardware designs, and antennas, that enables radio frequency based charging for electronic devices. The company was founded by Michael Aaron Leabman in 2012 and is headquartered in San Jose, CA.

Energous Corp

Energous Corp is seeing heightened investor attention following a series of positive catalysts, including record annual revenue growth and the strategic expansion of its Ambient IoT platform into European markets. While the community is actively debating the company's long-term commercial scalability and the potential for a short squeeze given its low-float status, some investors are highlighting recent insider activity and institutional accumulation as signs of a structural turnaround.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a significant leadership overhaul that replaced CEO Peter Greenleaf with Chairman Kevin Tang, a move widely interpreted by the community as a strategic signal that the company is being positioned for a potential buyout. Investors are actively debating the implications of this transition, including the acquisition of Kezar Life Sciences and the potential for Tang to leverage the companys remaining assets, such as Lupkynis and the Aritinercept pipeline, to maximize shareholder value.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is currently capturing significant attention as investors react to a major financing update where the company secured a substantial investment from Middle Eastern sovereign wealth funds, de-risking its merger with Warner Bros. Discovery. While the stock experiences volatile price action, the community is actively debating the implications of upcoming shareholder votes, potential short squeezes due to heavy short interest, and the long-term value proposition of new warrant distributions for existing shareholders.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

ProShares UltraPro QQQ is currently a focal point for investors navigating significant market volatility driven by escalating geopolitical tensions in the Middle East and concerns over oil supply disruptions. The community is actively debating the impact of these macro events on growth stocks, with many traders utilizing the ETF for aggressive short-term scalping, hedging, or capturing leveraged moves amid shifting sentiment regarding ceasefire negotiations.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense market volatility and price sensitivity as investors react to the stalled U.S.-Iran negotiations regarding the Strait of Hormuz. While some community members view the current price action as a bear trap amidst institutional accumulation, others are bracing for deeper pullbacks, with sentiment heavily influenced by the interplay between ongoing geopolitical tensions and broader macroeconomic signals.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is currently seeing increased market interest following the commissioning of its phase 1a commercial magnet production line in Stillwater, Oklahoma, which positions the company to begin fulfilling orders. The community is actively debating the company's long-term production potential and geopolitical significance against ongoing short-selling pressure and concerns regarding sector-wide regulatory hurdles.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR...

Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?

AI, Diagnostics and Next-Gen Materials Drive Innovation Push Across Emerging Growth Stocks

A wave of developments across emerging technology and life sciences companies underscores how artificial intelligence, advanced diagnostics, and next-generation biomaterials are converging to reshape several high-growth sectors. $ISPC, $AIFF, $KBLB, $BIAF, $ACXP, $KIDZ

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business...

Best Pharmaceutical Stocks To Follow Now - March 11th

Eli Lilly and Company, Pfizer, Vertex Pharmaceuticals, AbbVie, Abbott Laboratories, Acurx Pharmaceuticals, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to...

Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?

Acurx Pharmaceuticals Inc shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session.read more...

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection Acurx...

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update Acurx Pharmaceuticals to Discuss Full Year and...

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

ACXP
Acurx Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACXP News

ACXPAcurx Pharmaceuticals Inc